Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment

References

• Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563–74.
   PubMed Web of Science ®Google Scholar
• van Hoeven L, Luime J, Han H, Vergouwe Y, Weel A. Identifying axial spondyloarthritis in Dutch primary care patients, ages 20–45 years, with chronic low back pain. Arthritis Care Res. 2014;66(3):446–53.
   Web of Science ®Google Scholar
• Braun J, Davis J, Dougados M, Sieper J, van der LS, van der HD. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(3):316–20.
   PubMed Web of Science ®Google Scholar
• Ward MM, Kuzis S. Medication toxicity among patients with ankylosing spondylitis. Arthritis Rheum. 2002;47(3):234–41.
   PubMedGoogle Scholar
• Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802–19.
   PubMed Web of Science ®Google Scholar
• Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75(7):1357–62.
   PubMed Web of Science ®Google Scholar
• Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13(9):1042.
   PubMed Web of Science ®Google Scholar
• Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, et al. Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol. 2016;111(12):1796–805.
   PubMed Web of Science ®Google Scholar
• Bojko J. Measurement of blood calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis. Reumatologia. 2017;1:18–24.
   Google Scholar
• Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, et al. Serum calprotectin as a biomarker for Crohn’s disease. J Crohns Colitis. 2013;7(12):e678–83.
   PubMedGoogle Scholar
• Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83.
   PubMed Web of Science ®Google Scholar
• Gracey E, Qaiyum Z, Almaghlouth I, Lawson D, Karki S, Avvaru N, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75(12):2124–32.
   PubMed Web of Science ®Google Scholar
• Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewe R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2016;75(8):1486–93.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013;72(1):23–8.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Sieper J. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. Curr Opin Rheumatol. 2014;26(4):377–83.
   PubMed Web of Science ®Google Scholar
• Bowness P. Hla-B27. Annu Rev Immunol. 2015;33:29–48.
   PubMed Web of Science ®Google Scholar
• Gill T, Asquith M, Rosenbaum JT, Colbert RA. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol. 2015;27(4):319–25.
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38(4):499–505.
   PubMed Web of Science ®Google Scholar
• Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–8.
   PubMed Web of Science ®Google Scholar
• Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16l:273–82.
   PubMedGoogle Scholar
• Pepper RJ, Wang H-H, Rajakaruna GK, Papakrivopoulou E, Vogl T, Pusey CD, et al. S100A8/A9 (calprotectin) is critical for development of glomerulonephritis and promotes inflammatory leukocyte-renal cell interactions. Am J Pathol. 2015;185(5):1264–74.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Hou J, Peng L, Zhang X, Jia L, Wang X, et al. The pro-apoptotic and pro-inflammatory effects of calprotectin on human periodontal ligament cells. PLoS One. 2014;9(10):e110421.
   PubMed Web of Science ®Google Scholar
• Cesaro A, Anceriz N, Plante A, Page N, Tardif MR, Tessier PA. An inflammation loop orchestrated by S100A9 and calprotectin is critical for development of arthritis. PLoS One. 2012;7(9):e45478.
   PubMed Web of Science ®Google Scholar
• Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16(6):713–7.
   PubMed Web of Science ®Google Scholar
• Klingberg E, Strid H, Stahl A, Deminger A, Carlsten H, Ohman L, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017;19(1):21.
   PubMedGoogle Scholar
• Duran A, Kobak S, Sen N, Aktakka S, Atabay T, Orman M. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosn J Basic Med Sci. 2016;16:71–4.
   PubMed Web of Science ®Google Scholar
• Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov. 2010;9(9):703–18.
   PubMed Web of Science ®Google Scholar
• Kido J, Hayashi N, Kataoka M, Nagata T. Calprotectin expression in human monocytes: induction by porphyromonas gingivalis lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-1beta. J Periodontol. 2005;76:437–42.
   Web of Science ®Google Scholar
• Huang L, Li J, Han Y, Zhao S, Zheng Y, Sui F, et al. Serum calprotectin expression as a diagnostic marker for sepsis in postoperative intensive care unit patients. J Interferon Cytokine Res. 2016;36(10):607–16.
   PubMed Web of Science ®Google Scholar
• Gupta L, Bhattacharya S, Agarwal V, Aggarwal A. Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease. Clin Rheumatol. 2016;35(12):3075–9.
   PubMed Web of Science ®Google Scholar